Original Article/BiliaryCombined vascular resection and analysis of prognostic factors for hilar cholangiocarcinoma
References (19)
Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis
An unusual tumor with distinctive clinical and pathological features. Am J Med
(1965)- et al.
The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients
J Am Coll Surg
(2012) - et al.
Surgical resection for hilar cholangiocarcinoma: experience improves resectability
HPB (Oxford)
(2012) - et al.
Portal vein resection using the no-touch technique with a hepatectomy for hilar cholangiocarcinoma
HPB (Oxford)
(2014) - et al.
Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not?
Surgery
(2007) - et al.
Combined portal vein resection in the treatment of hilar cholangiocarcinoma: a systematic review and meta-analysis
Eur J Surg Oncol
(2014) - et al.
Tumour size over 3 cm predicts poor short-term outcomes after major liver resection for hilar cholangiocarcinoma
By the HC-AFC-2009 group. HPB (Oxford)
(2015) - et al.
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct
Int J Radiat Oncol Biol Phys
(2007) - et al.
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Gut
(2012)
Cited by (25)
Surgical management, including the role of transplantation, for intrahepatic and peri-hilar cholangiocarcinoma
2024, European Journal of Surgical OncologySystematic review and meta-analysis of surgery for hilar cholangiocarcinoma with arterial resection
2022, HPBCitation Excerpt :In addition, no subgroup analysis on patients who had undergone neoadjuvant chemotherapy prior to resection was performed, as only one study reported on this subject. Regarding adjuvant chemotherapy three studies did not report on this outcome.20,21,23 Three studies reported that patients did not receive adjuvant chemotherapy.19,22,25
Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium
2018, HPBCitation Excerpt :While a trend was seen towards decreasing survival with VR, there were no statistically significant differences between groups. Several subsequent single- or two-institution studies in Japan, China, and the USA have failed to discern any statistically significant differences in survival in HC patients receiving no VR, PVR, or HAR7,9,13,22 (Table 4 for more detail). Despite the multi-institutional nature of the current dataset, hilar cholangiocarcinoma remains a rare disease entity, especially in the western hemisphere.
Three-dimensional visualization and evaluation of hilar cholangiocarcinoma resectability and proposal of a new classification
2023, World Journal of Surgical OncologyAdvances in surgical treatment of hilar cholangiocarcinoma
2023, China Journal of General SurgeryVascular involvements in cholangiocarcinoma: Tips and tricks
2023, Advances in Surgical and Medical Specialties
Published online October 21, 2015.